Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
New tools are needed to match cancer patients with effective treatments. Patient-derived organoids offer a high-throughput platform to personalize treatments and discover novel therapies. Currently, methods to evaluate drug response in organoids are limited because they overlook cellular heterogeneity. In this study, non-invasive optical metabolic imaging (OMI) of cellular heterogeneity was characterized in breast cancer (BC) and pancreatic cancer (PC) patient-derived organoids. Baseline heterogeneity was analyzed for each patient, demonstrating that single-cell techniques, such as OMI, are required to capture the complete picture of heterogeneity present in a sample. Treatment-induced changes in heterogeneity were also analyzed, further demonstrating that these measurements greatly complement current techniques that only gauge average cellular response. Finally, OMI of cellular heterogeneity in organoids was evaluated as a predictor of clinical treatment response for the first time. Organoids were treated with the same drugs as the patient's prescribed regimen, and OMI measurements of heterogeneity were compared to patient outcome. OMI distinguished subpopulations of cells with divergent and dynamic responses to treatment in living organoids without the use of labels or dyes. OMI of organoids agreed with long-term therapeutic response in patients. With these capabilities, OMI could serve as a sensitive high-throughput tool to identify optimal therapies for individual patients, and to develop new effective therapies that address cellular heterogeneity in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction
McInnes, L., Healy, J., & Melville, J. (2018) · arXiv · doi:10.48550/arxiv.1802.03426 · Cited by 7,101
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Primary, Secondary, and Meta-Analysis of Research
GLASS, G. V. (1976) · Educational Researcher · doi:10.3102/0013189x005010003 · Cited by 4,890
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., Corbo, V., Oni, T. E., Hearn, S. A., Lee, E. J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162024 · Cited by 2,590
Ryan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348 · cited 1×
“The dense fibrotic extracellular matrix surrounding pancreatic tumors can hinder drug delivery by reducing blood flow and raising interstitial fluid pressure (72, 73).”
BackgroundThe causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Organoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
A living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973 · cited 2×
“Gels were allowed to solidify at 37C, 5% CO2 in a cell incubator for 15–30min, and BC organoid media (9) was added.”
MethodZanoni, M., Piccinini, F., Arienti, C., Zamagni, A., Santi, S., Polico, R., Bevilacqua, A., & Tesei, A. (2016) · Scientific Reports · doi:10.1038/srep19103 · Cited by 1,144 · cited 1×
“and heterogeneity between hollow and solid organoids were also expected, as heterogeneity-driving gradients of oxygen and nutrients are known to form within solid tumor spheroids (70).”
BackgroundOrganoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E. M., Burkhart, R. A., Denroche, R. E., Jang, G.-H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0349 · Cited by 1,092
Cited by
Datta, R., Heaster, T. M., Sharick, J. T., Gillette, A. A., & Skala, M. C. (2020) · Journal of Biomedical Optics · doi:10.1117/1.jbo.25.7.071203 · Cited by 880
Self-citationPatient-derived organoids as a predictive biomarker for treatment response in cancer patients
Wensink, G. E., Elias, S. G., Mullenders, J., Koopman, M., Boj, S. F., Kranenburg, O. W., & Roodhart, J. M. L. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00168-1 · Cited by 323
Tumor microenvironment in glioblastoma: Current and emerging concepts
Sharma, P., Aaroe, A., Liang, J., & Puduvalli, V. K. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad009 · Cited by 314
Thorel, L., Perréard, M., Florent, R., Divoux, J., Coffy, S., Vincent, A., Gaggioli, C., Guasch, G., Gidrol, X., Weiswald, L.-B., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01272-5 · Cited by 236
Promises and challenges of organoid-guided precision medicine
Bose, S., Clevers, H., & Shen, X. (2021) · Med · doi:10.1016/j.medj.2021.08.005 · Cited by 213
Metadata
- Authors
- Sharick, J. T., Walsh, C. M., Sprackling, C. M., Pasch, C. A., Pham, D. L., Esbona, K., Choudhary, A., Garcia-Valera, R., Burkard, M. E., McGregor, S. M., Matkowskyj, K. A., Parikh, A. A., Meszoely, I. M., Kelley, M. C., Tsai, S., Deming, D. A., & Skala, M. C.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-05-15
- Volume
- 10
- Pages
- 553-553
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3025063128
- Cited by
- 142
- References
- 14
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment. https://app.cochat.ai/papers/10.3389/fonc.2020.00553
- The paper
- Sharick, J. T., Walsh, C. M., Sprackling, C. M., Pasch, C. A., Pham, D. L., Esbona, K., Choudhary, A., Garcia-Valera, R., Burkard, M. E., McGregor, S. M., Matkowskyj, K. A., Parikh, A. A., Meszoely, I. M., Kelley, M. C., Tsai, S., Deming, D. A., & Skala, M. C. (2020). Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment. Frontiers in Oncology. https://doi.org/10.3389/fonc.2020.00553
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.